The United Kingdom already has robust, domestic regimes in place for the safety, security, transport, use and disposal of nuclear and radioactive materials \u2013 including medical radioisotopes \u2013 throughout their lifecycle. These regimes will remain in place when Euratom arrangements no longer apply in the UK, ensuring we exit with certainty, clarity and control.<\/p>
The Government is continuing to prepare for all European Union exit scenarios and is confident that we will be able to continue to provide a seamless supply of medicines, including medical radioisotopes, to National Health Service patients from the moment we leave the EU.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-10-17T15:28:41.257Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-10-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Radioisotopes: Imports"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what progress has been made to secure trade agreements to ensure the security of supply of medical radioisotopes following Brexit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/281", "label" : {"_value" : "Biography information for Baroness Golding"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Golding"} ], "uin" : "HL10480"} , {"_about" : "http://data.parliament.uk/resources/829014", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/829014/answer", "answerText" : {"_value" : "
The Government is fully aware of the importance of medical radioisotopes and the reliance on nuclear medicine for diagnostic procedures in the National Health Service. The United Kingdom\u2019s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in the interest of both the UK and European Union to avoid disruption in the timely access of treatment to patients; and to ensure that cross-border trade with the EU is frictionless as possible. This will be part of the broader negotiations of the UK\u2019s future relations with the EU.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2018-02-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-02-01T15:22:50.483Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Radioisotopes: Imports"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what steps they are taking to ensure that the UK radiopharmaceutical supply after leaving Euratom might be relied upon to not have an impact on patients, in terms of (1) timeliness of delivery, and (2) the quantity supplied of radiopharmaceutical supplies produced (a) in the EU, and (b) outside the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1138", "label" : {"_value" : "Biography information for Lord Carlile of Berriew"} } , "tablingMemberPrinted" : [{"_value" : "Lord Carlile of Berriew"} ], "uin" : "HL4999"} , {"_about" : "http://data.parliament.uk/resources/753958", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/753958/answer", "answerText" : {"_value" : "
The Government is fully aware of the importance of molybdenum-99 and the reliance on this medical radioisotope for diagnostic procedures in the National Health Service. The United Kingdom\u2019s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in everyone\u2019s interest to not disrupt the timely access of treatment to patients and to ensure that cross-border trade with the European Union and Euratom is as frictionless as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:38:56.527Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Radioisotopes: Imports"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4286", "label" : {"_value" : "Biography information for Lord Mendelsohn"} } , "tablingMemberPrinted" : [{"_value" : "Lord Mendelsohn"} ], "uin" : "HL1104"} , {"_about" : "http://data.parliament.uk/resources/753959", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/753959/answer", "answerText" : {"_value" : "
The UK\u2019s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom.<\/p>
The import or export of medical radioisotopes, including molybdenum-99 is not subject to any Euratom licensing requirements.These isotopes are governed and regulated under the Euratom framework; however, Euratom places no restrictions on the export of medical isotopes to countries outside the EU.<\/p>
It is in everyone\u2019s interest to not disrupt the timely access of treatment to patients; and to ensure that cross-border trade with the EU and Euratom is as frictionless as possible.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3474", "label" : {"_value" : "Biography information for Baroness Anelay of St Johns"} } , "answeringMemberPrinted" : {"_value" : "Baroness Anelay of St Johns"} , "dateOfAnswer" : {"_value" : "2017-08-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-08-02T14:39:06.3Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "203"} , "answeringDeptShortName" : {"_value" : "Exiting the European Union"} , "answeringDeptSortName" : {"_value" : "Exiting the European Union"} , "date" : {"_value" : "2017-07-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Radioisotopes: Imports"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "Her Majesty's Government what terms they are seeking to agree with the European Union to ensure that no additional delays or restrictions are placed on imports of molybdenum-99 to the UK following the UK's departure from Euratom.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4286", "label" : {"_value" : "Biography information for Lord Mendelsohn"} } , "tablingMemberPrinted" : [{"_value" : "Lord Mendelsohn"} ], "uin" : "HL1105"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }